CIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB
D.L. No. 1800-OSP, 1804-B I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com
Website : www.kwalitypharma.com

To
The BSE Limited
Department of Corporate Services,
P.J. Towers, Dalal Street,
Mumbai-400001

Date: March 10, 2026

Scrip Code: 539997

Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 – Update on Bioequivalence (BE) Program – Successful Completion of Phase 1 by Kwality Pharmaceuticals Ltd.

Dear Sir/Madam,

Kwality Pharmaceuticals Ltd. (KPL) had initiated an extensive **Bioequivalence (BE)** program covering more than 30 molecules across key therapeutic segments, including Oncology, Cardiology, Anti-diabetics, and Anti-hypertensives. The portfolio comprises a balanced mix of both patented and off-patent complex molecules. To execute this initiative, KPL has partnered with four globally accredited Contract Research Organizations (CROs).

The program has been structured in a phased manner to ensure efficient execution and regulatory alignment. We are pleased to announce the successful completion of Phase 1, with BE studies for **Hydroxycarbamide, Nilotinib, and Liposomal Amphotericin B** completed successfully.

These dossiers are now prepared for submission across regulated, semi-regulated, and Rest of the World (ROW) markets, further strengthening KPL's global regulatory footprint and commitment to expanding access to high-quality pharmaceutical products.

The above is for your information and dissemination to the stakeholders.

Thanking You,

For Kwality Pharmaceuticals Limited

KWALITY PHARMACEUTICALS LTD. MAJITHA ROAD NAG KALAN AMRITSAR INDIA

Aditya Arora
Whole Time Director & CFO
DIN: 07320410